These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study. Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388 [No Abstract] [Full Text] [Related]
31. Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. Rams A; Żółciński M; Zastrzeżyńska W; Polański S; Serafin A; Wilańska J; Musiał J; Bazan-Socha S J Asthma; 2018 Dec; 55(12):1384-1386. PubMed ID: 29300536 [TBL] [Abstract][Full Text] [Related]
32. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE; Figliomeni M; Spector S Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179 [TBL] [Abstract][Full Text] [Related]
33. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Esquivel A; Busse WW; Calatroni A; Togias AG; Grindle KG; Bochkov YA; Gruchalla RS; Kattan M; Kercsmar CM; Khurana Hershey G; Kim H; Lebeau P; Liu AH; Szefler SJ; Teach SJ; West JB; Wildfire J; Pongracic JA; Gern JE Am J Respir Crit Care Med; 2017 Oct; 196(8):985-992. PubMed ID: 28608756 [TBL] [Abstract][Full Text] [Related]
34. Real-life long-term omalizumab therapy in children with severe allergic asthma. Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964 [No Abstract] [Full Text] [Related]
35. Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus? Hamada S; Kuroe A; Tsukino M Rev Port Pneumol (2006); 2017; 23(5):303-304. PubMed ID: 28602732 [No Abstract] [Full Text] [Related]
36. Omalizumab in the treatment of asthma. Tan R; Corren J Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161 [TBL] [Abstract][Full Text] [Related]
37. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. Chipps BE; Lanier B; Milgrom H; Deschildre A; Hedlin G; Szefler SJ; Kattan M; Kianifard F; Ortiz B; Haselkorn T; Iqbal A; Rosén K; Trzaskoma B; Busse WW J Allergy Clin Immunol; 2017 May; 139(5):1431-1444. PubMed ID: 28477722 [TBL] [Abstract][Full Text] [Related]
38. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Tat TS; Cilli A Ann Allergy Asthma Immunol; 2016 Nov; 117(5):546-549. PubMed ID: 27788886 [TBL] [Abstract][Full Text] [Related]
40. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Kupryś-Lipińska I; Molińska K; Kuna P Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]